'Low' faecal immunochemical test (FIT) colorectal cancer: a 4-year comparison of the Nottingham '4F' protocol with FIT10 in symptomatic patients

被引:2
|
作者
Bailey, J. A. [1 ,2 ,8 ]
Morton, A. J. [1 ,2 ,3 ,4 ]
Jones, J. [1 ]
Chapman, C. J. [5 ]
Oliver, S. [6 ]
Morling, J. R. [6 ,7 ]
Patel, H. [6 ]
Humes, D. J. [1 ,3 ,4 ]
Banerjea, A. [1 ]
机构
[1] Nottingham Univ Hosp NHS Trust, Nottingham Colorectal Serv, Nottingham, England
[2] Univ Nottingham, Queens Med Ctr, Sch Med, Nottingham, England
[3] Nottingham Univ Hosp NHS Trust, NIHR Nottingham Biomed Res Ctr BRC, Nottingham, England
[4] Univ Nottingham, Nottingham, England
[5] Nottingham Univ Hosp NHS Trust, Bowel Canc Screening Programme, Eastern Hub, Nottingham, England
[6] NHS Nottingham & Nottinghamshire Integrated Care B, Nottingham, England
[7] Univ Nottingham, City Hosp, Sch Med, Lifespan & Populat Hlth, Nottingham, England
[8] Nottingham Univ Hosp NHS Trust, Nottingham Colorectal Serv, E Floor West Block,QMC Campus, Nottingham NG7 2UH, England
关键词
blood tests; colorectal cancer; digital rectal examination; Faecal immunochemical testing; COHORT; RISK;
D O I
10.1111/codi.16848
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Aim: The aim of this work was to evaluate colorectal cancer (CRC) outcomes after 'low' (sub-threshold) faecal immunochemical test (FIT) results in symptomatic patients tested in primary care.Method: This work comprised a retrospective audit of 35 289 patients with FIT results who had consulted their general practitioner with lower gastrointestinal symptoms and had subsequent CRC diagnoses.The Rapid Colorectal Cancer Diagnosis pathway was introduced in November 2017 to allow incorporation of FIT into clinical practice. The local '4F' protocol combined FIT results with blood tests and digital rectal examination (DRE): FIT, full blood count, ferritin and finger [DRE]. The outcome used was detection rates of CRC, missed CRC and time to diagnosis in local 4F protocols for patients with a subthreshold faecal haemoglobin (fHb) result compared with thresholds of 10 and 20 mu g Hb/g faeces.Results: A single threshold of 10 mu g Hb/g faeces identifies a population in whom the risk of CRC is 0.2%, but this would have missed 63 (10.5%) of 599 CRCs in this population. The Nottingham 4F protocol would have missed fewer CRCs [42 of 599 (7%)] despite using a threshold of 20 mu g Hb/g faeces for patients with normal blood tests. Subthreshold FIT results in patients subsequently diagnosed with a palpable rectal tumour yielded the longest delays in diagnosis.Conclusion: A combination of FIT with blood results and DRE (the 4F protocol) reduced the risk of missed or delayed diagnosis. Further studies on the impact of such protocols on the diagnostic accuracy of FIT are expected. The value of adding blood tests to FIT may be restricted to specific parts of the fHb results spectrum.
引用
收藏
页码:309 / 316
页数:8
相关论文
共 11 条
  • [1] Faecal immunochemical testing (FIT) for colorectal cancer in symptomatic primary care patients
    Hunt, N.
    Allcock, R.
    Myers, M.
    CLINICA CHIMICA ACTA, 2019, 493 : S153 - S153
  • [2] Guidance on faecal immunochemical testing (FIT) to help diagnose colorectal cancer among symptomatic patients in primary care
    Jones, Nicholas R.
    Round, Thomas
    Nicholson, Brian D.
    BRITISH JOURNAL OF GENERAL PRACTICE, 2023, 73 (731): : 283 - 285
  • [3] Still FIT for Purpose? Learning From False Negative Faecal Immunochemical Tests in Symptomatic Colorectal Cancer Patients
    Louden, E.
    Rao, P.
    Oo, K.
    BRITISH JOURNAL OF SURGERY, 2024, 111
  • [4] Adherence to Colorectal Cancer Screening: 4 Rounds of Fecal Immunochemical Test (FIT) Based Screening
    van der Vlugt, Manon
    Grobbee, Esmee J.
    Kuipers, Ernst J.
    Lansdorp-Vogelaar, Iris
    Essink-Bot, Marie-Louise
    Bossuyt, Patrick
    Spaander, Manon
    Dekker, Evelien
    GASTROENTEROLOGY, 2016, 150 (04) : S755 - S755
  • [5] How many Colorectal cancer patients had negative Faecal Immunochemical Testing (FIT) within the previous 1 year?
    Taufik, Abdulahad
    Johnston, Dorothy
    Coulston, Rachael
    McElvanna, Kevin
    Neill, Adrian
    BRITISH JOURNAL OF SURGERY, 2024, 111
  • [6] A COMPARISON OF EARLY POSTOPERATIVE OUTCOMES BETWEEN FECAL IMMUNOCHEMICAL TEST (FIT)-SCREENED AND SYMPTOMATIC PATIENTS UNDERGOING SURGERY FOR COLORECTAL CANCER.
    Khorasani, S.
    Telford, J.
    Khorasani, M.
    Brown, C.
    Karimuddin, A.
    Phang, T.
    Raval, M.
    DISEASES OF THE COLON & RECTUM, 2016, 59 (05) : E230 - E230
  • [7] Diagnostic accuracy for colorectal cancer of a quantitative faecal immunochemical test in symptomatic primary care patients: a study protocol
    Loov, Anna
    Hogberg, Cecilia
    Lilja, Mikael
    Theodorsson, Elvar
    Hellstrom, Per
    Metsini, Alexandra
    Olsson, Louise
    DIAGNOSTIC AND PROGNOSTIC RESEARCH, 2022, 6 (01)
  • [8] Diagnostic accuracy of the faecal immunochemical test for colorectal cancer in symptomatic patients: comparison with NICE and SIGN referral criteria
    Cubiella, J.
    Salve, M.
    Diaz-Ondina, M.
    Vega, P.
    Alves, M. T.
    Iglesias, F.
    Sanchez, E.
    Macia, P.
    Blanco, I.
    Bujanda, L.
    Fernandez-Seara, J.
    COLORECTAL DISEASE, 2014, 16 (08) : O273 - O282
  • [9] Comparison of the QuikRead go® point-of-care faecal immunochemical test for haemoglobin with the FOB Gold Wide® laboratory analyser to diagnose colorectal cancer in symptomatic patients
    Maclean, William
    Zahoor, Zahida
    O'Driscoll, Shane
    Piggott, Carolyn
    Whyte, Martin B.
    Rockall, Timothy
    Jourdan, Iain
    Benton, Sally C.
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2022, 60 (01) : 101 - 108
  • [10] Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year followup from CheckMate 142
    Andre, T.
    Lonardi, S.
    Wong, K.
    Lenz, H.
    Gelsomino, F.
    Aglietta, M.
    Morse, M.
    Van Cutsem, E.
    McDermott, R.
    Hill, A.
    Sawyer, M.
    Hendlisz, A.
    Neyns, B.
    Abdullaev, S.
    Memaj, A.
    Lei, M.
    Kopetz, S.
    Overman, M.
    ANNALS OF ONCOLOGY, 2021, 32 : S213 - S214